However, the Heart Protection Study compared the vascular protective effects of simvastatin among 6 groups of patients with acute coronary syndrome and different fasting CRP levels, and found that simvastatin resulted in a significant reduction of vascular events (including coronary death, myocardial infarction, stroke, and revascularisation), but it did not modify the vascular benefits among groups with different baseline CRP levels37. This evidence concerns the gene CRP and myocardial infarction.